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The study of regenerative medicine has the potential to help
scientists and clinicians devise early-intervention treatments
for traumatic injury or degenerative diseases, by regrowth or
replacement of cells or tissues. Originally an outgrowth from the
ﬁeld of tissue engineering and deﬁned as the practice of replacing
damaged tissues and organs or stimulating the body's own repair
mechanisms to heal, regenerative medicine has now expanded to
encompass the use of stem cells for modelling disease as well as
autologous transplant and therapeutic delivery of functional
molecules, the production of tissues and organs in a dish, the
role of immune function in tissue repair, and the burgeoning area
of biomedical engineering. Regenerative medicine is highly
cross-disciplinary and serves as a bridge between basic science
and clinical medicine.
npj Regenerative Medicine—a new Nature Partner Journal
at the forefront of this rapidly growing research ﬁeld—will
enable researchers and clinicians alike to keep abreast of
global developments in regenerative medicine. The open-access
format of the journal means that all articles will be free to
read upon publication, enabling greater reach in a timely fashion
to the wider community interested in this topic, especially
clinicians.
CURRENT CHALLENGES IN REGENERATIVE MEDICINE
A popular view is that emerging technologies disappoint in the
short term and over-deliver in the long term, and it will be another
20–30 years before the full clinical beneﬁt of regenerative
medicine is realised. For the foreseeable future, much of
the research in this area remains conﬁned to the bench
rather than the bedside, but clinical translation is becoming
apparent.
There are many challenges in regenerative medicine, but three
are noteworthy as npj Regenerative Medicine publishes its
ﬁrst articles. First, elucidation of the mechanistic aspects of
embryonic development is crucial to understanding the repair
of living cells and extracellular material in situ;1 however, the ﬁeld
is far from yielding therapeutically applicable outcomes from this
knowledge.
Second, studying adult tissue turnover and replacement in an
evolutionary context, using efﬁciently regenerating vertebrate
species such as ﬁsh or salamander to analyse mechanisms of
repair, often seems remote from a mammalian perspective,2 and
relatively slow to yield mechanistic information.
Third, current approaches that rely heavily on stem cell
transplantation and regenerative medicine have had minimal
impact on clinical medicine so far,3 presumably because our
understanding of the basic biology underlying tissue repair is still
far from exhaustive.
These impediments notwithstanding, the potential for regen-
erative medicine to redress the increasing prevalence of
degenerative diseases in a globally ageing population has
attracted huge scientiﬁc and public interest.
BEYOND STEM CELLS
Recent advances in our basic knowledge of the pathogenesis and
histogenesis involved in tissue damage and regeneration
have combined with remarkable progress in stem cell biology
such that the prospect of clinical tissue repair strategies is a
tangible reality.4 Examples include injection of stem cells or
progenitor cells; induction of regeneration by biologically
active molecules or inductive scaffolds administered alone or
as a secretion by infused cells; immunomodulation of the
scarring response; and transplantation of in vitro grown organs
and tissues.
While there has been justiﬁable excitement around the use of
pluripotent stem cells in regenerative medicine, how endogenous
stem cells function in different tissues will need to be integrated
with the biology of tissue repair. Alongside the efforts to
understand the biology of transplanted cells, an equal attempt
may be required to understand the recipient tissue stroma and
provide the appropriate microenvironment for the transplanted
cells to successfully integrate and repair tissue.5 The development
of in vitro three-dimensional culture environments that prompt
self-organisation of stem cells into organoids will be of particular
relevance to disease modelling and treatment in the context of
regenerative medicine.6
THE INTERPLAY BETWEEN TISSUE STEM CELLS AND THE
SURROUNDING NICHE
Within the context of a body, cells rarely display autonomy, but
continually interact with other cells and the extracellular matrix
(ECM) that surrounds and physically supports them. Studies in
embryonic development and adult tissues have identiﬁed
speciﬁc niches that help to control the proliferation and
fate of resident stem cells. The niche is typically composed of
the ECM and the resident cells, including macrophages, myoﬁ-
broblasts and other immune cells. Together, these niche
components help instruct and condition adult progenitor cells
to promote appropriate tissue repair.7 Capitalising upon these
events for therapeutic purposes will be particularly challenging in
the setting of both acute and chronic organ injury, where signals
and cellular controls underlying homeostatic replacement of
healthy tissue have been distorted, rendering the patient’s body
less receptive to transplanted cells in the absence of normal
trophic signals.
Although a variety of possible scenarios has been proposed,
effective stem cell therapy in the future will likely involve
strategies for ensuring their effective function by including
inductive micro-environmental niche factors with or without
ECM within the target tissue to optimise survival and function of
transplanted cells. Alternatively, the use of temporary niches
surrounding individual transplanted cells may be required to
provide appropriate survival signals. In this regard, there is an
increasing recognition of a central, perhaps orchestrating role for
immune cells in providing trophic signals to transplanted cells,
preparing the ground for physiological tissue repair.
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IMMUNE CELLULAR PLAYERS IN TISSUE REPAIR
Among the panoply of immune cells involved in the response to
both acute and chronic wounds, recent ﬁndings have highlighted
novel and often unexpected roles for select immune cell types in
promoting a salutary environment for effective cell replacement
and restoration of tissue integrity.8 Although cell therapy is
currently a popular approach for replacing stem cells or
somatic cells within a tissue, and immune suppression has been
a focus of therapy, it now seems likely that immune stimulation
can have positive paracrine or trophic effects upon the damaged
tissue.
A rapid resolution of the pro-inﬂammatory phase and transition
to the regeneration phase is crucial to the outcome of tissue
damage, and its dysregulation may aggravate complex diseases
and prevent repair. With a better understanding of the intimate
relationship between immune components and affected tissues,
assessment and modulation of circulating immune cells in
recovering patients may provide additional clues to the extent
of tissue damage and accelerate the progress of tissue
regeneration.9 Stated differently, just as developmental biology
and regenerative medicine have overlap and areas of common
interest, immunology and regenerative medicine also have
previously unrecognised areas of overlap with tremendous
diagnostic and therapeutic potential.
TISSUE-SPECIFIC FEATURES OF REGENERATION
Effective tissue regeneration proceeds in sequential phases,
including inﬂammation, tissue formation and maturation involving
a complex orchestration of epithelial and mesenchymal
cell interplay with tissue-resident and recruited immune cells.
In efﬁciently regenerating vertebrates, this scenario plays out in a
timely fashion irrespective of tissue type, whereas in mammals
a remarkable disparity exists between the regenerative capacity
of various tissues and organs. Thus, liver, gut, skin, kidney,
skeletal muscle, heart and CNS each display unique cellular
responses and signalling mechanisms in response to damage. For
some organs where repair is an evolutionarily conserved feature
(such as liver), insightful mechanistic experiments in other
organisms can often be of relevance in mammalian systems,
whereas the regenerative capacity of other organs, such as the
heart or CNS, vary widely across species, making comparative
studies of particular interest.
EMERGING TRENDS IN DEVELOPING CLINICAL THERAPIES FOR
TISSUE REGENERATION
Although our understanding of the basic mechanisms of tissue
repair is still far from complete, understanding how stem cells
work in context and how diseases develop during our lifespan is a
crucial ﬁrst step in the process of developing new treatments. The
rapid clinical translation currently occurring in regenerative
medicine means an increasing number of ‘ﬁrst-in-human’ tissue
reconstructive studies are likely, some common features of which
are below:
1. The role of the immune system in tissue regeneration may
provide clues for intervening in both the somatic cell and the
immune response to tissue injury, by using small-molecule
approaches as well as biological agents such as cytokines.
As with the treatment of human autoimmune and
inﬂammatory diseases, assessment of the molecular
heterogeneity between patient immune responses in traumatic
or chronic injury settings may provide vital clues to the
progression of disease, and prompt design of personalised
therapies.
2. Clinical tissue repair through the safe delivery of exogenous
cells, be they stem cells or immune cells, entails a substantial
degree of infrastructure. Implantation of composite tissues
grown ex vivo would require a facility for cell growth and
artiﬁcial biomaterials, as well as a clinical trials facility with
regulatory permission, high-resolution clinical imaging and
access to molecular-pathology-level tissue analysis. This
multi-disciplinary environment for the clinical delivery of
regenerative therapies will engage clinical research centres
with a broad focus on regenerative medicine or an existing
transplant program.
3. Progressive imaging of regenerating tissues and organs will be
required in humans, after the stimulation of endogenous
repair or the transplantation of exogenous cells, and onwards
during the ageing process. Conventional imaging modalities
such as MRI scanning can be used to ensure that abnormal
tissue growth, such as tumours, do not form. Functional
imaging that can assess tissue improvement and accompany-
ing metabolic signatures would be ideal and would
allow comparison to the original diseased and healthy
‘control’ tissue. Deviation from the healthy imaging ‘signatures’
could be understood as an early warning signal that the
cells and tissues are not performing as expected, and
intervention in regenerative therapy may be required. The
ﬁeld will also beneﬁt from precision medical approaches to
characterise individual genetic variations that may affect
regenerative potential, and uncover new personalised targets
for intervention.
The goal of npj Regenerative Medicine is to track, inform
and inspire accelerated discovery in this fast-moving ﬁeld
to foster clinical translation. Cross-cutting studies are clearly the
emerging modus operandi, and npj Regenerative Medicine
will capture this new wave, encouraging multidisciplinarity,
setting trends with forward-looking commentaries and
spirited interchanges, and highlighting the emerging marriage
of approaches, ranging from basic variation in regenerative
capacity to clinical applications. Our ﬁrst articles provide
valuable information on therapeutic gene delivery and
multigene knockout strategies, as well as novel stem cell
targets for treating muscular dystrophy and a meeting review
covering recent developments in the ﬁeld. We are encouraged
by the high quality of the content, and look forward to your
future contributions!
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